Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Amgen
Pfizer
Pfizer
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
Cancer Research UK
Tianjin Medical University